BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25617725)

  • 1. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
    Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
    J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.
    Rüger R; Tansi FL; Rabenhold M; Steiniger F; Kontermann RE; Fahr A; Hilger I
    J Control Release; 2014 Jul; 186():1-10. PubMed ID: 24810115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.
    Schuster L; Seifert O; Vollmer S; Kontermann RE; Schlosshauer B; Hartmann H
    Mol Pharm; 2015 Sep; 12(9):3146-57. PubMed ID: 26181293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
    Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
    J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.
    Tansi FL; Rüger R; Böhm C; Steiniger F; Kontermann RE; Teichgraeber UK; Fahr A; Hilger I
    Acta Biomater; 2017 May; 54():281-293. PubMed ID: 28347861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).
    Nettelbeck DM; Miller DW; Jérôme V; Zuzarte M; Watkins SJ; Hawkins RE; Müller R; Kontermann RE
    Mol Ther; 2001 Jun; 3(6):882-91. PubMed ID: 11407902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105).
    Völkel T; Hölig P; Merdan T; Müller R; Kontermann RE
    Biochim Biophys Acta; 2004 May; 1663(1-2):158-66. PubMed ID: 15157618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.
    Baum P; Müller D; Rüger R; Kontermann RE
    J Drug Target; 2007 Jul; 15(6):399-406. PubMed ID: 17613658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes.
    Korn T; Müller R; Kontermann RE
    J Immunother; 2004; 27(2):99-106. PubMed ID: 14770081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
    Brünker P; Wartha K; Friess T; Grau-Richards S; Waldhauer I; Koller CF; Weiser B; Majety M; Runza V; Niu H; Packman K; Feng N; Daouti S; Hosse RJ; Mössner E; Weber TG; Herting F; Scheuer W; Sade H; Shao C; Liu B; Wang P; Xu G; Vega-Harring S; Klein C; Bosslet K; Umaña P
    Mol Cancer Ther; 2016 May; 15(5):946-57. PubMed ID: 27037412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.
    Zhang J; Valianou M; Simmons H; Robinson MK; Lee HO; Mullins SR; Marasco WA; Adams GP; Weiner LM; Cheng JD
    FASEB J; 2013 Feb; 27(2):581-9. PubMed ID: 23104982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
    Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
    J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
    Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
    J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated immunoliposome-loaded endoglin single-chain antibody enhances anti-tumor capacity of porcine α1,3GT gene.
    Huang Y; Huang Y; He J; Wang H; Luo Y; Li Y; Liu J; Zhong L; Zhao Y
    Biomaterials; 2019 Oct; 217():119231. PubMed ID: 31254933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
    Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cloning, expression, purification and characterization of a bispecific single-chain diabody against fluoroquinolones and sulfonamides in Escherichia coli.
    Chen M; Wen K; Tao X; Xie J; Wang L; Li Y; Ding S; Jiang H
    Protein Expr Purif; 2014 Aug; 100():19-25. PubMed ID: 24816423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.